DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Whether NY Medicaid covers Wegovy, Zepbound, Ozempic, or Mounjaro for weight loss and type 2 diabetes, prior authorization rules, and routes when coverage is denied.
NY Medicaid comprehensive; PA approval high for documented obesity. Submit prior authorization through your prescriber, not directly. Approval decisions typically take 3-10 business days; expedited reviews for urgent cases process within 72 hours. Denials are appealable; first-round appeals succeed roughly 30-40% of the time when supporting documentation is thorough.
If NY Medicaid denies coverage, the practical routes are: (1) manufacturer cash-pay channels like NovoCare Direct (Wegovy at $499/month) and LillyDirect (Zepbound at $549/month), (2) compounded semaglutide or tirzepatide via telehealth (lower price but not FDA-approved; supply tightening after the May 2026 shortage resolution), or (3) charity care through patient assistance programs offered by Novo Nordisk and Eli Lilly for low-income patients.
NY telehealth parity strong; out-of-state collaboration permitted. Major telehealth providers operating in New York include form health, ro body, sequence ww, plushcare weight loss.
Most active obesity medicine market on East Coast.
Editorial summary, not legal or medical advice. State Medicaid policies change frequently. Confirm current status with NY Medicaid member services or your prescriber.